Premium
Low‐dose mitomycin and weekly low‐dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5‐fluorouracil
Author(s) -
Colozza Mariantonietta,
Tonato Maurizio,
Grignani Fausto,
Davis Stephen
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880715)62:2<262::aid-cncr2820620206>3.0.co;2-c
Subject(s) - medicine , cyclophosphamide , chemotherapy , regimen , fluorouracil , doxorubicin , neutropenia , methotrexate , gastroenterology , combination chemotherapy , surgery , mitomycin c
Forty‐four evaluable patients with breast carcinoma previously treated with combination chemotherapy consisting of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) were treated with a combination chemotherapy regimen consisting of doxorubicin (A) (20 mg/m 2 on days 1,8,15, and 22, repeated every 28 days) and mitomycin (MIT) (10 mg/m 2 on day 1, repeated every 28 days). Five patients (11%) achieved a complete remission (CR) and 14 patients (32%) had a partial response (PR). The median duration of survival was 11.5 months and the median duration of response was 8 months for responders (CR and PR). Toxicity was moderate and consisted of neutropenia (74%), thrombocytopenia (25%), pneumonitis (11%), and cardiomyopathy (2%). The combination chemotherapy regimen A and MIT is an effective regimen for treating patients previously treated with CMF.